Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Intratumoral BO-112 combined with systemic anti–PD-1 shows immunotherapeutic potential to control tumors in patients primarily refractory to anti–PD-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 1×
“Although the correlation of response or clinical benefit with gene expression profiling or IHC is preliminary due to the small number of patients, increased IFN gene expression and T cell infiltration are consistent with tumor microenvironment changes seen in patients responding to immune checkpoint blockade (22, 23).”
BackgroundSelf-citationDefining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
RNA sensors of the innate immune system and their detection of pathogens
Chen, N., Xia, P., Li, S., Zhang, T., Wang, T. T., & Zhu, J. (2017) · IUBMB Life · doi:10.1002/iub.1625 · Cited by 225
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
“I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
BackgroundSelf-citationCancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Self-citationIntratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Self-citationResistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Metadata
- Authors
- Márquez-Rodas, I., Longo, F., Rodriguez-Ruiz, M. E., Calles, A., Ponce, S., Jove, M., Rubio-Viqueira, B., Perez-Gracia, J. L., Gómez-Rueda, A., López-Tarruella, S., Ponz-Sarvise, M., Álvarez, R., Soria-Rivas, A., de Miguel, E., Ramos-Medina, R., Castañon, E., Gajate, P., Sempere-Ortega, C., Jiménez-Aguilar, E., Aznar, M. A., Calvo, A., Lopez-Casas, P. P., Martín-Algarra, S., Martín, M., Tersago, D., Quintero, M., & Melero, I.
- Venue
- Science Translational Medicine
- Published
- 2020-10-14
- Volume
- 12
- Issue
- 565
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3093384692
- Cited by
- 88
- References
- 5
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors. https://app.cochat.ai/papers/10.1126/scitranslmed.abb0391
- The paper
- Márquez-Rodas, I., Longo, F., Rodriguez-Ruiz, M. E., Calles, A., Ponce, S., Jove, M., Rubio-Viqueira, B., Perez-Gracia, J. L., Gómez-Rueda, A., López-Tarruella, S., Ponz-Sarvise, M., Álvarez, R., Soria-Rivas, A., de Miguel, E., Ramos-Medina, R., Castañon, E., Gajate, P., Sempere-Ortega, C., Jiménez-Aguilar, E., . . . Melero, I. (2020). Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abb0391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.